Trial Chairman: Paul M Ridker, MD
The JUPITER Trial (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) was amulticenter, randomized, double-blind, placebo-controlled 4-year trial fundedby AstraZeneca to assess whether rosuvastatin (20 mg daily) can prevent major cardiovascular events among nearly 18,000 healthy men aged 55 and older and women aged 65 and older with normal levels of low-density lipoprotein (LDL) cholesterol but elevated levels of C-reactive protein, a marker of chronic low-level inflammation. The trial was stopped ahead of schedule in 2008 becauseof a statistically extreme 44% reduction in risk for a first majorcardiovascular event among the group of participants assigned torosuvastatin. Click here for a summary of the study’s main results.
Related Press Releases:
Rosuvastatin Dramatically Reduces Heart Attack, Stroke and Total Mortality Among Men, Women with Low Cholesterol but Elevated C-Reactive Protein Level
Lowering Levels of Both Cholesterol and Inflammation with Statin Therapy Significantly Improves Cardiovascular Outcomes
New Data From JUPITERTrial Finds Statin Therapy Reduces Risk of Dangerous Blood Clots
CRP indicates heart disease risk (video about JUPITER trial results)
Serendipity and collaboration shaped BWH inflammation story (Part I of II)
Team effort led to success of JUPITER (Part II of II)